Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul:165:89-97.
doi: 10.1016/j.urology.2021.08.070. Epub 2021 Nov 20.

Disparities in the Treatment and Survival of Metastatic Renal Cell Carcinoma

Meredith R Metcalf  1 , Vanessa N Peña  2 , Joseph G Cheaib  2 , Arnav Srivastava  3 , Phillip M Pierorazio  2 , Hiten D Patel  4
Affiliations

Disparities in the Treatment and Survival of Metastatic Renal Cell Carcinoma

Meredith R Metcalf et al. Urology. 2022 Jul.

Abstract

Objective: To evaluate racial, gender, and socioeconomic differences in the treatment of metastatic renal cell carcinoma (mRCC) and their impact on survival.

Methods: Patients aged ≥18 years diagnosed with mRCC in the National Cancer Database (2004-2015) were analyzed. Multivariable logistic regression models were used to evaluate factors associated with systemic therapy and cytoreductive nephrectomy (CN) utilization. Cox proportional hazards regression models were used to evaluate overall survival.

Results: In total, 31,989 patients with mRCC were identified with 30.2% receiving CN, 51.6% receiving systemic therapy, and 25.8% receiving no treatment. Females were at lower odds of receiving systemic therapy (OR 0.91, P <.01) and increased odds of no treatment (OR 1.14, P <.01). Non-Hispanic Black and Hispanic patients were at decreased odds of receiving CN (OR 0.75, P <.01 and OR 0.86, P = .01, respectively). Black patients were at decreased odds of receiving systemic therapy (OR 0.85, P <.01) and increased odds of no treatment (OR 1.41, P <.01). Adjusting for demographic and disease variables, Black patients were at increased risk of death (HR 1.06, P = .03), largely due to less use of systemic therapy and CN; survival differences disappeared after accounting for receipt of therapy (HR 0.99, P = .66).

Conclusion: There are racial, gender, and socioeconomic differences in the treatment of mRCC which are associated with a disparity in overall survival. Dismantling systemic barriers and improving access to care may lead to reduced disparities and improved outcomes for mRCC.

PubMed Disclaimer

Comment in

  • EDITORIAL COMMENT.
    Lee BR, Batai K. Lee BR, et al. Urology. 2022 Jul;165:96-97. doi: 10.1016/j.urology.2021.08.073. Urology. 2022. PMID: 35843703 No abstract available.

Similar articles

See all similar articles

Cited by

LinkOut - more resources